Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2023, vol. 32, nr 8, August, p. 909–920

doi: 10.17219/acem/158781

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cite as:


Wang N, Jiang D, Zhou C, Han X. Alpha-solanine inhibits endothelial inflammation via nuclear factor kappa B signaling pathway. Adv Clin Exp Med. 2023;32(8):909–920. doi:10.17219/acem/158781

Alpha-solanine inhibits endothelial inflammation via nuclear factor kappa B signaling pathway

Nan Wang1,A,C,D,F, Daquan Jiang2,B,C,E,F, Chunxiu Zhou3,B,E,F, Xi Han4,A,E,F

1 Department of Orthopaedics, Zhejiang Chinese Medical University Affiliated Jiangnan Hospital, Hangzhou, China

2 Outpatient Department of Surgery, Zhejiang Chinese Medical University Affiliated Jiangnan Hospital, Hangzhou, China

3 Department of Nursing, Zhejiang Chinese Medical University Affiliated Jiangnan Hospital, Hangzhou, China

4 School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China

Graphical abstract


Graphical abstracts

Abstract

Background. Alpha-solanine (α-solanine) is the main glycoalkaloid in potato plants. It possesses anticarcinogenic properties and exerts toxic effects. Alpha-solanine can regulate the nuclear factor kappa B (NF-κB) signaling pathway in cancer cells and macrophages. However, little is known about the anti-inflammatory effects and the related molecular mechanisms of α-solanine on endothelial cells.

Objectives. This study aims to examine the effects of α-solanine on endothelial inflammation in vitro, and to evaluate its influence on regulating the NF-κB signaling pathway.

Materials and methods. Tumor necrosis factor alpha (TNF-α)-pcDNA3.1(+) plasmid vector was constructed and transfected into human umbilical vein endothelial cells (HUVECs). The expression of TNF-α was examined with quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot. Following treatment with α-solanine or the specific NF-κB inhibitor SN50 for 24 h, cell viability was detected using Cell Counting Kit-8 (CCK-8) assay. Interleukin 6 (IL-6) and TNF-α levels in cell supernatant were detected using enzyme-linked immunosorbent assay (ELISA). The relative protein levels of phospho-P65 (p-P65), phospho-inhibitor of NF-κBα (p-IκBα) and IκB kinase (IKK) α/β were examined with western blot.

Results. The α-solanine inhibits TNF-α-induced inflammatory injury in HUVECs. Compared with control cells, the cell viability was significantly decreased, the levels of TNF-α and IL-6 were significantly increased, and the relative protein levels of p-P65, p-IκBα and IKKα/β were significantly upregulated in TNF-α-overexpressed cells. The treatment with α-solanine or SN50 decreased the levels of TNF-α and IL-6, and downregulated the relative protein levels of p-P65, p-IκBα and IKKα/β in TNF-α-overexpressed HUVECs.

Conclusions. This study demonstrated for the first time that α-solanine inhibits endothelial inflammation through the NF-κB signaling pathway. The α-solanine was suggested to be an inhibitor of the NF-κB signaling pathway in endothelial cells. The anti-inflammatory effect of α-solanine may provide a new perspective for the prevention and treatment of phlebitis.

Key words: TNF-α, NF-κB signaling pathway, inflammatory reaction, α-solanine

 

Background

Peripheral intravenous infusion is widely used in modern medical practice. Phlebitis is a common complication associated with intravenous therapies.1 The incidence of phlebitis with peripheral intravenous catheter use is 10.5% in hospitalized adult patients in China,1 whereas it is as high as 53% in hospitalized pediatric patients in Jordan.2 Phlebitis is a chemical or mechanical inflammation caused by a long-term intravenous infusion of high-concentration, highly irritant drugs or placement of irritant interventional catheters.1, 3, 4, 5 The routine treatments for phlebitis, such as the external application of magnesium sulfate or mucopolysaccharide polysulfate cream, are unsatisfactory.6, 7, 8 Therefore, developing new strategies for the prevention and treatment of phlebitis caused by intravenous infusion is needed. Potato glycoalkaloids, the naturally occurring steroidal glycoalkaloids, are well known for their toxicity and antimicrobial activity.9, 10, 11, 12, 13 Alpha-solanine (α-solanine) is one of the major glycoalkaloids in potato plants.10 Previous studies about α-solanine mostly center on its anticarcinogenic properties and toxicant effects.14, 15, 16 It has been reported that α-solanine could promote tumor cell apoptosis, inhibit cell proliferation and suppress angiogenesis.17, 18, 19, 20, 21, 22 In addition, α-solanine plays important roles in chemical protection and chemotherapy.23, 24, 25 Shin et al. investigated the anti-inflammatory effect of α-solanine on cultured macrophages in a mouse model of endotoxenia, and the results suggested that α-solanine may be a promising therapeutic agent against inflammatory diseases.26

It has been indicated that the role of α-solanine in cancer cells and macrophages is associated with the nuclear factor kappa B (NF-κB) signaling pathway.26, 27, 28 It is a prototypical pro-inflammatory signaling pathway that can be activated by various cytokines, including tumor necrosis factor alpha (TNF-α).29 The NF-κB family consists of 5 proteins: p65, cRel, RelB, p50, and p52. Among them, p65 possesses a transactivation domain and therefore can affect transcription. In resting cells, NF-κB proteins exist in the cytoplasm as inactive forms by binding to their inhibitory proteins IκBs. The IκBα is the prototypical member of the IκB family. The activation of NF-κB depends on IκBα phosphorylation. The IκBα phosphorylation can stimulate ubiquitination and proteasomal degradation, leading to the nuclear translocation of liberated NF-κB, and subsequently the transcription of inflammatory molecules. The phosphorylation of IκB proteins is regulated by IκB kinases (IKK): IKKα and IKKβ.30, 31 Dysregulated NF-κB signaling can cause an imbalance of immune homeostasis, leading to autoimmune diseases, chronic inflammatory diseases and cancers.32, 33, 34 In addition, the activation of the NF-κB signaling pathway is involved in the inflammation-induced activation of the tryptophan-kynurenine metabolic system and mitochondrial impairment, which is implicated in neurodegenerative diseases and psychiatric disorders.35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 The SN50 is a specific NF-κB inhibitor that could suppress the translocation of the NF-κB active complex into the nucleus.46, 47 It has been reported that SN50 can attenuate inflammation in lung injury and traumatic brain injury.48, 49

The anti-inflammatory effect of α-solanine has been reported in macrophages; however, the effect of α-solanine on endothelial inflammation and the related mechanisms have not been reported until now. Elucidating the effects of α-solanine on endothelial inflammation in vitro as well as evaluating its influence on the NF-κB signaling pathway could provide an experimental basis for the clinical management of phlebitis.

Objectives

This study aims to examine the effects of α-solanine on endothelial inflammation in TNF-α-overexpressed human umbilical vein endothelial cells (HUVECs). Furthermore, whether α-solanine regulates the TNF-α-induced NF-κB signaling pathway was explored.

Materials and methods

Cells and transfection

The HUVECs (BNCC249736) were provided by Beijing Beina Chuanglian Institute of Biotechnology (Beijing, China) and cultured in Endothelial Cell Medium (1001; ScienCell, Carlsbad, USA). The cells were incubated at 37°C in a humidified atmosphere of 5% CO2. The α-solanine (20562-02-1) was purchased from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China), and SN50 (HY-P0151) from MedChemExpress (Monmouth Junction, USA). The pcDNA3.1(+) (P0157) was provided by Wuhan Miaoling Biotechnology Co., Ltd. (Wuhan, China). Before transfection, the TNF-α overexpression vector (TNF-α-pcDNA3.1(+) plasmid vector) was prepared. The pcDNA3.1(+) plasmid vector was digested with XhoI (ER0691; Thermo Fisher Scientific, Waltham, USA). The sequences of the TNF-α gene were amplified and inserted into the pcDNA3.1(+) vector. The ligated vector was transformed into Trans5α Chemically Competent Cell (CD201-01; TransGen Biotech Co., Ltd.) and the positive clones were selected. The TNF-α-pcDNA3.1(+) and pcDNA3.1(+) plasmids were extracted using the Endo-free Plasmid Mini Kit II (D6950-01; Omega Bio-Tek, Norcross, USA) and verified through enzyme digestion. Cell transfection was performed using Lipofectamine 3000 (L3000015; Thermo Fisher Scientific).50, 51 The HUVECs were seeded in 6-well plates at a density of 5×105 cells per well and allowed to grow to 70% confluence. Then, the cells were incubated in fresh medium without serum. Next, 5 μL Lipofectamine 3000 was diluted with 125 μL opti-MEM medium and incubated with the diluted plasmid (2.5 μg plasmid DNA diluted in 125 μL opti-MEM medium (Thermo Fisher Scientific) and 5 μL Lipofectamine 3000) for 15 min at room temperature. The HUVECs were incubated with 250 μL DNA-liposome complexes (containing 10 µL Lipofectamine 3000 and 2.5 µg plasmid DNA) at 37°C for 4 h, and then the medium was refreshed. At 48 h following transfection, the cells were treated with 10 μg/mL α-solanine or 5 mg/mL SN50 for 24 h.52, 53 Cells transfected with the empty plasmid vector pcDNA3.1(+) were called the vector group.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Ultrapure RNA Kit (CW0581M; CWBIO, Beijing, China) was used for RNA extraction. The RNA concentrations were measured under an ultraviolet spectrophotometer (NP80, NanoPhotometer; Implen GmbH, Munich, Germany). Reverse transcription was performed to synthesize cDNA using a commercial kit (R223-0; Vazyme Biotech Co., Ltd., Nanjing, China) and qRT-PCR was performed with SYBR Green reagents (A4004M; LifeInt, Xiamen, China). The reaction system contained 1 μL cDNA, 10 μL 2×SYBR Green PCR Master Mix, 0.4 μL upstream and downstream primers, and 8.2 μL dH2O without RNase. Cycling parameters were 10 min at 95°C for initial denaturation, then 40 cycles of 10 s at 95°C for denaturation, 30 s at 58°C for annealing, and 30 s at 72°C for extension. The primer sequences of TNF-α were 5’-CGAGTGACAAGCCTGTAGCC-3’ (upstream) and 5’-TGAAGAGGACCTGGGAGTAG-3’ (downstream). The primer sequences of β-actin were 5’-TGGCACCCAGCACAATGAA-3’ (upstream) and 5’-CTAAGTCAGATTCCGCTAGAGAAGCA-3’ (downstream). Relative TNF-α mRNA expression levels were calculated using the 2−ΔΔCq method.54 The β-actin was used as the housekeeping gene.

Western blot

The cells were lysed with radioimmunoprecipitation assay (RIPA) Lysis Buffer (C1053; Applygen Technologies Inc., Beijing, China) and incubated on ice for 20 min. After centrifugation at 12,000 rpm for 10 min, the concentration of proteins in the supernatant was determined using a bicinchoninic acid (BCA) kit. Equal amounts of protein were separated using sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by transferring onto a polyvinylidene fluoride (PVDF) membrane (IPVH00010; Millipore, Boston, USA). The membrane was blocked in nonfat milk and incubated overnight with the specific antibody at 4°C. Mouse monoclonal anti-actin (TA-09) was purchased from Zhongshan Jinqiao Biotechnology Co., Ltd. (Beijing, China). Rabbit anti-P65 (10745-1-ap) and rabbit anti-inhibitor of NF-κB (anti-IκBα) (10268-1-ap) were obtained from Proteintech Group Inc. (Chicago, USA). Rabbit anti-phospho-P65 (af2006), rabbit anti-IκB kinase (IKK) α/β (af6014), and rabbit anti-phospho-IκBα (af2002) were purchased from Affinity Biosciences (Cincinnati, USA). These antibodies were used at a dilution of 1:1000. After washing with Tris-buffered saline with Tween 20 (TBST), the membrane was incubated with the secondary antibody, including peroxidase-conjugated goat anti-mouse IgG (H+L) (ZB-2305) and peroxidase-conjugated goat anti-rabbit IgG (H+L) (ZB-2301) at a 1:2000 dilution for 2 h at room temperature. These secondary antibodies were from Zhongshan Jinqiao Biotechnology Co., Ltd (Beijing, China). The signals were visualized by the hypersensitive luminescent solution (RJ239676; Thermo Fisher Scientific) with a chemiluminescence imaging system (ChemiDoc XRS+; Bio-Rad, Hercules, USA).

CCK-8 assay

Cell Counting Kit-8 (CCK-8) assay was performed to examine cell viability. This assay uses a tetrazolium salt WST-8 (water-soluble tetrazolium 8), which produces the orange-colored formazan when 2 electrons are received from viable cells through an electron mediator, 1-Methoxy phenazinium methylsulfate (PMS), by nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH). The amount of formazan is dependent on the number of living cells. After washing with phosphate-buffered saline (PBS), 5×103 cells were plated into the 96-well plate. The α-solanine was dissolved in absolute ethanol. The next day, 1, 3, 6, 9, or 12 μL of α-solanine (1 mg/mL) were added to treat the cells for 24 h. The medium was then refreshed and 10 μL of CCK-8 was added into the wells and incubated for 2 h at 37°C. Optical densities were measured with an automatic microplate reader (WD-2102B; Beijing Liuyi Biotechnology Co., Ltd., Beijing, China) at a wavelength of 450 nm.

ELISA

The TNF-α and IL-6 concentrations in cell supernatant were measured with the Human TNF-α enzyme-linked immunosorbent assay (ELISA) Kit (MM-0122H1; Jiangsu Meimian Industrial Co., Ltd., Yancheng, China) and Human IL-6 ELISA Kit (MM-0049H1; Jiangsu Meimian Industrial Co., Ltd.), respectively, following the manufacturer’s protocols. Briefly, 50 μL standards with different concentrations or 50 μL samples were added to the wells. Then, 100 μL of enzyme-labeled reagents were added to each well, except for the blank well, and incubated at 37°C for 60 min. After washing with washing buffer 5 times, 50 μL substrates A and B were added and the plates were incubated in the dark at 37°C for 15 min. Then, 50 μL termination solution was added to each well and the optical density (OD) values at a wavelength of 450 nm were measured within 15 min.

Statistical analyses

The IBM SPSS v. 20.0 software (IBM Corp., Armonk, USA) was used to analyze statistical data. Each sample was selected independently. Kruskal–Wallis H test (K–W test) followed by Dunn–Bonferroni test (D–B test) was performed to compare the differences between multiple groups. All the statistical values of pairwise comparisons between the groups using D–B test for post hoc testing are shown in Table 1. Statistical significance was defined as p < 0.05.

Results

Effect of different concentrations of α-solanine on the viability of HUVECs

Different concentrations of α-solanine were used to treat HUVECs for 24 h. Then, the cell viabilities were measured using the CCK-8 assay. As shown in Figure 1A, HUVEC viability was significantly decreased by treatment with 30 μg/mL, 60 μg/mL, 90 μg/mL, and 120 μg/mL α-solanine (K–W test: H = 44.802, df = 5, p < 0.001). Cell viability was not affected by treatment with 10 μg/mL α-solanine (D–B test, p = 1.000). Therefore, we chose α-solanine at the concentration of 10 μg/mL to conduct the following experiments.

Effect of α-solanine on cell viability
of TNF-α-overexpressed HUVECs

The TNF-α overexpression vector was constructed and transfected into HUVECs, and TNF-α expression levels in HUVECs were examined with western blot and qRT-PCR. The results in Figure 1B show that, compared with the TNF-α negative control vector (pcDNA3.1(+) plasmid vector)-transfected cells, both the TNF-α relative mRNA expression level (D–B test, p = 0.048) and the TNF-α relative protein expression level (D–B test, p = 0.010) in the TNF-α overexpression vector-transfected cells were significantly increased. The CCK-8 assay demonstrated that, compared with the vector group, cell viability was significantly decreased in the TNF-α group (D–B test, p = 0.009). The difference in cell viability between the TNF-α + α-solanine group and the TNF-α group was not significant (D–B test, p = 1.000) (Figure 1C).

Effect of α-solanine on TNF-α
and IL-6 protein levels
in TNF-α-overexpressed HUVECs

An ELISA was used to detect TNF-α and interleukin 6 (IL-6) protein levels in the cell supernatant of HUVECs. The results presented in Figure 2 show that, compared with the vector group, TNF-α (D–B test, p < 0.001) and IL-6 protein levels (D–B test, p < 0.001) were significantly increased in the TNF-α group. In TNF-α-overexpressed cells, α-solanine significantly decreased the elevated protein levels of TNF-α (D–B test, p = 0.015) and IL-6 (D–B test, p = 0.001).

Effect of α-solanine on phospho-inhibitor of NF-κBα (p-IκBα), phospho-P65 (p-P65) and IKKα/β relative protein expression levels in TNF-α-overexpressed HUVECs

The p-IκBα, p-P65 and IKKα/β relative protein expression levels in TNF-α-overexpressed HUVECs were determined using western blot assay. We found that the relative protein expression levels of p-IκBα (D–B test, p < 0.001), p-P65 (D–B test, p = 0.001) and IKKα/β (D–B test, p = 0.018) were significantly increased in the TNF-α group compared with the vector group. However, in TNF-α-overexpressed HUVECs, the increased p-IκBα (D–B test, p = 0.032), p-P65 (D–B test, p = 0.021) and IKKα/β (D–B test, p = 0.001) relative protein expression levels were significantly suppressed by treatment with α-solanine (Figure 3).

Effect of SN50 on cell viability,
as well as IL-6 and TNF-α levels
in TNF-α-overexpressed HUVECs

The SN50 is a specific NF-κB inhibitor that could suppress the translocation of the NF-κB active complex into the nucleus. To evaluate whether α-solanine has a similar function to that of SN50, the cells were treated with 5 mg/mL SN50 for 24 h. As shown in Figure 4A, SN50 did not affect the cell viability of TNF-α-overexpressed HUVECs (D–B test, p = 1.000). As shown in Figure 4B, both the TNF-α level (D–B test, p < 0.001) and the IL-6 level (D–B test, p = 0.005) were significantly increased in TNF-α-overexpressed HUVECs; however, SN50 treatment suppressed the elevated TNF-α (D–B test, p = 0.002) and IL-6 (D–B test, p < 0.001) levels.

Effect of SN50 on p-IκBα, p-P65
and IKKα/β relative protein expression levels in TNF-α-overexpressed HUVECs

The results presented in Figure 5 demonstrate that p-IκBα (D–B test, p = 0.001), p-P65 (D–B test, p = 0.043) and IKKα/β (D–B test, p = 0.001) relative protein expression levels were increased in the cells transfected with the TNF-α vector compared with the cells transfected with the pcDNA3.1(+) vector. The SN50 treatment significantly suppressed the increased p-IκBα (D–B test, p = 0.048), p-P65 (D–B test, p = 0.041) and IKKα/β (D–B test, p = 0.004) relative protein expression levels in TNF-α-overexpressed HUVECs.

Discussion

The present study demonstrated the effects of α-solanine on inflammation in HUVECs. The α-solanine inhibited the expression of TNF-α and IL-6 in TNF-α-overexpressed HUVECs, and these effects were related to the suppression of the NF-κB signaling pathway.

Phlebitis is an inflammation of the vein. Vascular endothelial cells make up the innermost surface of blood vessels. Inflammatory injury and apoptosis of endothelial cells are observed in many human diseases, including phlebitis.55, 56, 57 In the present study, TNF-α was overexpressed in HUVECs to establish a model of venous endothelial inflammation. Consistent with the previous report revealing that TNF-α can induce inflammatory injury,58 our study showed that TNF-α increased IL-6 expression, activated the NF-κB signaling pathway and inhibited the proliferation of HUVECs. These results demonstrated that TNF-α can induce inflammation injury in endothelial cells.

A large number of studies have confirmed the toxic effects of α-solanine on cancers.14, 15, 16, 23, 24 Only a limited number of studies investigated the anti-inflammatory effect of α-solanine on macrophages and in endotoxemia model mice.26, 59 Kenny et al. reported that α-solanine possesses anti-inflammatory properties in lipopolysaccharide (LPS)-induced Raw264.7 macrophages59 by reducing the production of nitric oxide (NO) and decreasing the levels of pro-inflammatory cytokines. This study provided more evidence for the anti-inflammatory effect of α-solanine. We investigated the anti-inflammatory effect of α-solanine in endothelial cells. Similar to the effects in LPS-induced macrophages, α-solanine inhibited the expression of the pro-inflammatory mediators TNF-α and IL-6 in TNF-α-overexpressed endothelial cells. The suppression of TNF-α and IL-6 can prevent inflammatory injury and apoptosis of HUVECs.60, 61 Taken together, this evidence suggests that α-solanine can inhibit inflammatory injury of HUVECs. It is noteworthy that the levels of IL-6 and TNF-α in the TNF-α + α-solanine group were significantly higher than in the control group, suggesting that α-solanine may not eliminate the effect of TNF-α overexpression on IL-6 and TNF-α elevation in HUVECs. However, α-solanine could alleviate endothelial inflammation, thus showing a positive role in the treatment of phlebitis.

The NF-κB pathway is considered the most typical inflammatory pathway, and many inflammatory mediators are found downstream of NF-κB.62, 63 The study by Lu et al. showed that α-solanine downregulates the nuclear content of NF-κB in human melanoma cells.28 In human hepatocellular carcinoma HepG2 cells, α-solanine-induced oxidative stress is associated with the NF-κB pathway.27 Natural or synthetic NF-κB inhibitors could prevent LPS-induced injury in endothelial cells by decreasing the levels of inflammatory factors.64, 65 In the current study, we investigated the effect of α-solanine on the NF-κB signaling pathway in endothelial cells and found that α-solanine inhibited TNF-α-induced NF-κB signaling pathway activation in HUVECs by decreasing p-IκBα, p-P65 and IKKα/β relative protein expression levels. Our results were consistent with the reports on LPS-induced macrophages and endotoxemia model mice which demonstrated that α-solanine abrogates inflammatory responses by inhibiting the NF-κB signaling pathway. We found that p-IκBα was not significantly decreased in the TNF-α + α-solanine group compared with the control group. However, p-IκBα was significantly decreased in the TNF-α + α-solanine group compared with the TNF-α group. These results indicate that α-solanine may not eliminate the effect of TNF-α overexpression on IκBα phosphorylation in HUVECs. However, α-solanine shows an inhibitory effect on the phosphorylation of IκBα in TNF-α-overexpressed HUVECs. Taken together, this evidence suggests that α-solanine protects against inflammatory diseases via NF-κB suppression. Previous studies have shown other molecules and signaling pathways that were regulated by α-solanine, such as matrix metalloproteinases (MMPs), Akt/mTOR signaling pathway, STAT3 signaling pathway, and ERK and PI3K/Akt signaling pathways.20, 28, 66, 67, 68 Whether these molecules and signaling pathways are involved in the effect of α-solanine on protecting against endothelial inflammation is still unknown. The molecular mechanisms underlying the effect of α-solanine on endothelial inflammation need to be further explored.

In the present study, we found that the effects of α-solanine on TNF-α-overexpressed HUVECs seem to be similar to that of SN50. The activation of the NF-κB pathway leads to the nuclear translocation of NF-κB protein and the activation of downstream genes.69 The SN50 is a specific NF-κB inhibitor that could suppress the translocation of the NF-κB active complex into the nucleus. We demonstrated that both α-solanine and SN50 could decrease the relative expression levels of proteins in the NF-κB signaling pathway, such as p-IκBα, p-P65 and IKKα/β. These results suggested that α-solanine can act as an NF-κB inhibitor in the process of inflammatory injury in HUVECs. However, we did not examine the nuclear translocation of NF-κB proteins. To confirm the possibility of α-solanine as an NF-κB inhibitor, a study investigating the effect of α-solanine on NF-κB nuclear translocation will be carried out in the future.

This study demonstrated the inhibitory effect of α-solanine on endothelial inflammation in vitro. Further studies need to be performed on phlebitis animal models and phlebitis patients to confirm the anti-inflammatory effect of α-solanine in vivo. Expanding the application of α-solanine on other inflammatory diseases may be a good research direction in the future. Potato glycoside alkaloids are a group of easily obtained natural steroid compounds. Studies on the function of α-solanine in inflammation will provide a new perspective for the prevention and treatment of phlebitis, as well as new ideas for the research and development of potato glycoside alkaloids.

Limitations

There are 3 major limitations to this study. First, we only investigated the anti-inflammatory effects of α-solanine in vitro. The therapeutic effect of α-solanine on phlebitis in vivo needs to be confirmed on animal models in our further studies. Second, to fully elucidate the effect of α-solanine on inflammatory response in HUVECs, more inflammatory factors and mechanisms that are related to inflammation need to be examined. Third, TNF-α-transfected cells are not a good model of inflammation. The use of endotoxin or inflammatory agents will better induce inflammation.

Conclusions

This is the first in vitro study demonstrating that α-solanine inhibits endothelial inflammation through the NF-κB signaling pathway. The findings support the potential application of α-solanine for the clinical management of phlebitis and describe the molecular mechanism underlying the protective function of α-solanine against endothelial inflammation.

Tables


Table 1. Statistic values of pairwise comparisons between the groups using the Dunn–Bonferroni test for post hoc testing

Group−group

Viability

Group−group

TNF-α

Group−group

Viability

IL-6

TNF-α

p-IκBα

p-P65

IKKα/β

Group−group

Viability

IL-6

TNF-α

p-IκBα

p-P65

IKKα/β

mRNA

protein

0–10

6.111

C–V

0.000

0.000

C–α

13.056

1.556

−4.611

6.833

−9.917

4.000

C–V

10.944

−10.889

−0.444

7.333

−6.667

4.667

0–30

22.000*

C–T

−9.000*

−9.000*

C–V

8.222

−5.222

−4.722

0.500

0.000

1.083

C–T

30.222*

−32.556*

−29.278*

−21.154*

−21.167*

−15.667*

0–60

27.222*

V–T

−9.000*

−9.000*

C–T

33.778*

−37.222*

−38.222*

−25.500*

−24.833*

−20.750*

C–V+S

15.056

−5.778

−6.389

7.167

−2.833

2.333

0–90

28.111*

C–V+α

22.944*

−19.222

−17.778

−11.667

−5.417

−1.917

C–T+S

32.111*

23.556*

−20.278*

20.333*

−15.167*

−14.751*

0–120

42.889*

C–T+α

42.333*

−28.222*

−29.000*

−19.500*

−18.833*

−18.750*

V–T

19.278*

−21.667*

−28.833*

−20.500*

−14.500*

−20.333*

10–30

15.889

α–V

−4.833

−6.778

−0.111

7.333

9.917

−5.083

V–V+S

4.111

5.111

−5.944

−0.167

3.833

−2.333

10–60

21.111

α–T

20.722

−38.778*

33.611*

6.000

−14.917

6.000

V–T+S

21.167*

−17.778*

−19.833*

−14.500*

18.333*

−14.333*

10–90

22.000*

α–V+α

9.889

−20.778

−13.167

−4.833

4.500

−5.917

T–V+S

−15.156

9.000

9.000

−7.167

−8.500

6.000

10–120

36.778*

α–T+α

29.278*

9.000

9.222

−12.167

−8.917

−14.750

T–T+S

1.889

26.778*

22.889*

−14.333*

−14.791*

18.000*

30–60

5.222

V–T

25.556*

−32.000*

−33.500*

−26.000*

−24.833*

19.667*

V+S–T+S

17.056

−12.667

−13.889

6.000

6.000

−9.667

30–90

6.111

V–V+α

14.722

14.000

−13.056

−12.167

−5.417

−0.833

30–120

20.889

V–T+α

34.111*

−23.000*

−24.278*

−20.000*

−18.833*

18.833*

60–90

0.889

T–V+α

−10.833

18.000

20.444

13.833

6.000

−13.667

60–120

15.667

T–T+α

8.556

−29.778*

24.389*

−18.667*

19.417*

−24.750*

90–120

14.778

V+α–T+α

19.389

−9.000

−11.222

−7.833

−13.417

−12.833

* p < 0.05; C – control; V – vector; T – TNF-α; α – α-solanine; S – SN50; IL-6 – interleukin 6; TNF-α – tumor necrosis factor alpha; p-P65 – phospho-P65; p-IκBα – phosphor–inhibitor of NF-κB α; IKK – IκB kinase.

Figures


Fig. 1. Effects of α-solanine on cell viability of tumor necrosis factor alpha (TNF-α)-overexpressed human umbilical vein endothelial cells (HUVECs). A. Cell viability of HUVECs under the treatment of different concentrations of α-solanine. Data were analyzed with Kruskal–Wallis H (K–W) test followed by Dunn–Bonferroni (D–B) test (K–W test: H = 44.802, degrees of freedom (df) = 5, p < 0.001; * p < 0.05 compared to 0 μg/mL, n = 5); B. TNF-α relative mRNA expression level and TNF-α relative protein expression level in HUVECs after the transfection of the pcDNA3.1(+) plasmid vector or the TNF-α overexpression vector. Data were analyzed using K–W test followed by D–B test (K–W test: mRNA, H = 23.143, df = 2, p < 0.001; protein, H = 11.439, df = 2, p = 0.003; * p < 0.05 compared to vector; # p < 0.05 compared to TNF-α, n = 3); C. Effects of α-solanine treatment on the cell viability of HUVECs transfected with TNF-α vector. Data were analyzed with K–W test followed by D–B test (K–W test: H = 46.700, df = 5, p < 0.001; * p < 0.05 compared to control; # p < 0.05 compared to vector; n = 5)
Fig. 2. Effects of α-solanine on tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) protein levels in TNF-α-overexpressed cells. Data were analyzed with Kruskal–Wallis H (K–W) test followed by Dunn–Bonferroni test (K–W test: TNF-α, H = 42.863, degrees of freedom (df) = 5, p < 0.001; IL-6, H = 46.571, df = 5, p < 0.001; * p < 0.05 compared to control; # p < 0.05 compared to vector; @ p < 0.05 compared to TNF-α; n = 3)
Fig. 3. Effect of α-solanine on phospho-inhibitor of NF-κBα (p-IκBα), phospho-P65 (p-P65) and IκB kinase (IKK) α/β relative protein expression levels in tumor necrosis factor alpha (TNF-α)-overexpressed cells. Data were analyzed with Kruskal–Wallis H (K–W) test followed by Dunn–Bonferroni test (K–W test: p-IκBα, H = 29.841, degrees of freedom (df) = 5, p < 0.001; p-P65, H = 28.052, df = 5, p < 0.001; IKKα/β, H = 25.441, df = 5, p < 0.001; * p < 0.05 compared to control; # p < 0.05 compared to vector; @ p < 0.05 compared to TNF-α; n = 3)
Fig. 4. Effects of SN50 on (A) cell viability (data were analyzed with Kruskal–Wallis H (K–W) test followed by Dunn–Bonferroni test (K–W test: H = 38.110, df = 4, p < 0.001)), as well as (B) the protein levels of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) in TNF-α-overexpressed cells (data were analyzed with K–W test followed by Dunn–Bonferroni test (K–W test: TNF-α, H = 35.143, degrees of freedom (df) = 4, p < 0.001; IL-6, H = 36.906, df = 4, p < 0.001; * p < 0.05 compared to control; # p < 0.05 compared to vector; @ p < 0.05 compared to TNF-α; n = 5 for cell viability and n = 3 for TNF-α and IL-6 protein levels))
Fig. 5. Effect of SN50 on phospho-inhibitor of NF-κBα (p-IκBα), phospho-P65 (p-P65) and IκB kinase (IKK) α/β relative protein expression levels in tumor necrosis factor alpha (TNF-α)-overexpressed cells. Data were analyzed with Kruskal–Wallis H (K–W) test followed by Dunn–Bonferroni test (K–W test: p-IκBα, H = 25.011, degrees of freedom (df) = 4, p < 0.001; p-P65, H = 24.030, df = 4, p < 0.001; IKKα/β, H = 23.140, df = 4, p < 0.001; * p < 0.05 compared to control; # p < 0.05 compared to vector; @ p < 0.05 compared to TNF-α; n = 3)
p-P65 – phospho-P65; p-IκBα – phospho-inhibitor of NF-κB α; IKK – IκB kinase

References (69)

  1. Liu C, Chen L, Kong D, Lyu F, Luan L, Yang L. Incidence, risk factors and medical cost of peripheral intravenous catheter-related complications in hospitalised adult patients. J Vasc Access. 2022;23(1):57–66. doi:10.1177/1129729820978124
  2. Suliman M, Saleh W, Al-Shiekh H, Taan W, AlBashtawy M. The incidence of peripheral intravenous catheter phlebitis and risk factors among pediatric patients. J Pediatr Nurs. 2020;50:89–93. doi:10.1016/j.pedn.2019.11.006
  3. Manrique-Rodríguez S, Heras-Hidalgo I, Pernia-López MS, et al. Standardization and chemical characterization of intravenous therapy in adult patients: A step further in medication safety. Drugs Res Dev. 2021;21(1):39–64. doi:10.1007/s40268-020-00329-w
  4. Marsh N, Webster J, Ullman AJ, et al. Peripheral intravenous catheter non-infectious complications in adults: A systematic review and meta-analysis. J Adv Nurs. 2020;76(12):3346–3362. doi:10.1111/jan.14565
  5. Nicotera R. La flebite associata alla terapia endovenosa/infusionale. Assistenza Infermieristica e Ricerca. 2011;30(1):34–41. doi:10.1702/620.7244
  6. Wan Y. Observation for clinical effect of phellodendron wet compress in treating the phlebitis caused by infusion. Pak J Pharm Sci. 2018;31(3 Special):1099–1102. PMID:29735457.
  7. Zheng GH, Yang L, Chen HY, Chu JF, Mei L. Aloe vera for prevention and treatment of infusion phlebitis. Cochrane Database Syst Rev. 2014;2014(6):CD009162. doi:10.1002/14651858.CD009162.pub2
  8. Wang X, Lv X, Zhang J, Wang Y. Effect of Chahuang ointment on prevention of phlebitis from peripherally inserted central catheter: Randomized clinical trial. Rev Esc Enferm USP. 2021;55:e03680. doi:10.1590/s1980-220x2019008003680
  9. Friedman M. Chemistry and anticarcinogenic mechanisms of glycoalkaloids produced by eggplants, potatoes, and tomatoes. J Agric Food Chem. 2015;63(13):3323–3337. doi:10.1021/acs.jafc.5b00818
  10. Friedman M. Potato glycoalkaloids and metabolites: Roles in the plant and in the diet. J Agric Food Chem. 2006;54(23):8655–8681. doi:10.1021/jf061471t
  11. Korpan YI, Nazarenko EA, Skryshevskaya IV, Martelet C, Jaffrezic-Renault N, El’skaya AV. Potato glycoalkaloids: True safety or false sense of security? Trends Biotechnol. 2004;22(3):147–151. doi:10.1016/j.tibtech.2004.01.009
  12. Dhalsamant K, Singh CB, Lankapalli R. A review on greening and glycoalkaloids in potato tubers: Potential solutions. J Agric Food Chem. 2022;70(43):13819–13831. doi:10.1021/acs.jafc.2c01169
  13. Schrenk D, Bignami M, Bodin L, et al; EFSA Panel on Contaminants in the Food Chain (CONTAM). Risk assessment of glycoalkaloids in feed and food, in particular in potatoes and potato-derived products. EFSA J. 2020;18(8):e06222. doi:10.2903/j.efsa.2020.6222
  14. Hassan SH, Gul S, Zahra HS, et al. Alpha solanine: A novel natural bioactive molecule with anticancer effects in multiple human malignancies. Nutr Cancer. 2021;73(9):1541–1552. doi:10.1080/01635581.2020.1803932
  15. Luo S, Tian GJ, Yu FX, Wen ZD. A narrative review of the antitumor studies of solanine. Transl Cancer Res. 2021;10(3):1578–1582. doi:10.21037/tcr-20-3094
  16. Mohsenikia M, Alizadeh AM, Khodayari S, et al. The protective and therapeutic effects of alpha-solanine on mice breast cancer. Eur J Pharmacol. 2013;718(1–3):1–9. doi:10.1016/j.ejphar.2013.09.015
  17. Lv C, Kong H, Dong G, et al. Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo. PLoS One. 2014;9(2):e87868. doi:10.1371/journal.pone.0087868
  18. Yan X, Li M, Chen L, et al. α solanine inhibits growth and metastatic potential of human colorectal cancer cells. Oncol Rep. 2020;43(5):1387–1396. doi:10.3892/or.2020.7519
  19. Zou T, Gu L, Yang L, et al. Alpha-solanine anti-tumor effects in non-small cell lung cancer through regulating the energy metabolism pathway. Recent Pat Anticancer Drug Discov. 2022;17(4):396–409. doi:10.2174/1574892817666220113144635
  20. Shen KH, Liao A, Hung JH, et al. α-solanine inhibits invasion of human prostate cancer cell by suppressing epithelial–mesenchymal transition and MMPs expression. Molecules. 2014;19(8):11896–11914. doi:10.3390/molecules190811896
  21. Wang L, Sun QQ, Zhang SJ, et al. Inhibitory effect of α-solanine on esophageal carcinoma in vitro. Exp Ther Med. 2016;12(3):1525–1530. doi:10.3892/etm.2016.3500
  22. Ni X, Chen J, Lu F, et al. Anti-cancer effect of α-solanine by down-regulating S100P expression in colorectal cancer cells. Recent Pat Anticancer Drug Discov. 2018;13(2):240–247. doi:10.2174/1574892813666180329163945
  23. Wang Y, Wu J, Guo W, et al. α-solanine modulates the radiosensitivity of esophageal cancer cells by inducing microRNA 138 expression. Cell Physiol Biochem. 2016;39(3):996–1010. doi:10.1159/000447807
  24. Gu T, Yuan W, Li C, et al. α-solanine inhibits proliferation, invasion, and migration, and induces apoptosis in human choriocarcinoma JEG-3 cells in vitro and in vivo. Toxins. 2021;13(3):210. doi:10.3390/toxins13030210
  25. Nie X, Dai Y, Tan J, et al. α-solanine reverses pulmonary vascular remodeling and vascular angiogenesis in experimental pulmonary artery hypertension. J Hypertens. 2017;35(12):2419–2435. doi:10.1097/HJH.0000000000001475
  26. Shin JS, Lee KG, Lee HH, et al. Solanine isolated from Solanum tubero­sum L. cv Jayoung abrogates LPS-induced inflammatory responses via NF-κB inactivation in RAW 264.7 macrophages and endotoxin-induced shock model in mice. J Cell Biochem. 2016;117(10):2327–2339. doi:10.1002/jcb.25530
  27. Gouhar SA, Abo-Elfadl MT, Gamal-Eldeen AM, El-Daly SM. Involvement of miRNAs in response to oxidative stress induced by the steroidal glycoalkaloid α-solanine in hepatocellular carcinoma cells. Environ Toxicol. 2022;37(2):212–223. doi:10.1002/tox.23390
  28. Lu MK, Shih YW, Chang Chien TT, Fang LH, Huang HC, Chen PS. α-solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2/9 activities. Biol Pharm Bull. 2010;33(10):1685–1691. doi:10.1248/bpb.33.1685
  29. Hayden MS, Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin Immunol. 2014;26(3):253–266. doi:10.1016/j.smim.2014.05.004
  30. Hayden MS, Ghosh S. NF-κB, the first quarter-century: Remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203–234. doi:10.1101/gad.183434.111
  31. Ghosh S, Hayden MS. Celebrating 25 years of NF-κB research. Immunol Rev. 2012;246(1):5–13. doi:10.1111/j.1600-065X.2012.01111.x
  32. Mitchell JP, Carmody RJ. NF-κB and the transcriptional control of inflammation. Int Rev Cell Mol Biol. 2018;335:41–84. doi:10.1016/bs.ircmb.2017.07.007
  33. Peng C, Ouyang Y, Lu N, Li N. The NF-κB signaling pathway, the microbiota, and gastrointestinal tumorigenesis: Recent advances. Front Immunol. 2020;11:1387. doi:10.3389/fimmu.2020.01387
  34. Poma P. NF-κB and disease. Int J Mol Sci. 2020;21(23):9181. doi:10.3390/ijms21239181
  35. Ozer M, Ince S, Gündogdu B, et al. Effect of thiamine pyrophosphate on cyclophosphamide-induced oxidative ovarian damage and reproductive dysfunction in female rats. Adv Clin Exp Med. 2022;31(2):129–137. doi:10.17219/acem/142535
  36. Zhou A, Zhang S, Yang C, Liao N, Zhang Y. Dandelion root extracts abolish MAPK pathways to ameliorate experimental mouse ulcerative colitis. Adv Clin Exp Med. 2022;31(5):529–538. doi:10.17219/acem/146234
  37. Tosun M, Olmez H, Unver E, et al. Oxidative and pro-inflammatory lung injury induced by desflurane inhalation in rats and the protective effect of rutin. Adv Clin Exp Med. 2021;30(9):941–948. doi:10.17219/acem/136194
  38. Sun B, Liu Z, Yu Z. miRNA-323a-3p promoted intracranial, aneurysm-induced inflammation via AMPK/NF-κB signaling pathway by AdipoR1. Adv Clin Exp Med. 2022;31(11):1243–1254. doi:10.17219/acem/151053
  39. Zhuang S, Xu Q, Li Y, Hu K, Xia Z, Zhang L. Serum TBK1 levels are correlated with inflammation, optic nerve sheath diameter and intracranial pressure in severe traumatic brain injury patients under deep sedation [published online as ahead of print on November 30, 2022]. Adv Clin Exp Med. 2022. doi:10.17219/acem/155040
  40. Requena-Ocaña N, Flores-Lopez M, Papaseit E, et al. Vascular endothelial growth factor as a potential biomarker of neuroinflammation and frontal cognitive impairment in patients with alcohol use disorder. Biomedicines. 2022;10(5):947. doi:10.3390/biomedicines10050947
  41. Török N, Maszlag-Török R, Molnár K, et al. Single nucleotide polymorphisms of indoleamine 2,3-dioxygenase 1 influenced the age onset of Parkinson’s disease. Front Biosci (Landmark Ed). 2022;27(9):265. doi:10.31083/j.fbl2709265
  42. Tanaka M, Szabó Á, Spekker E, Polyák H, Tóth F, Vécsei L. Mitochondrial impairment: A common motif in neuropsychiatric presentation? The link to the tryptophan–kynurenine metabolic system. Cells. 2022;11(16):2607. doi:10.3390/cells11162607
  43. Tanaka M, Vécsei L. Editorial of Special Issue ‘Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection.’ Int J Mol Sci. 2022;23(13):6991. doi:10.3390/ijms23136991
  44. Tanaka M, Spekker E, Szabó Á, Polyák H, Vécsei L. Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders: Bioactive kynurenines and their analogues as neuroprotective agents. In celebration of 80th birthday of Professor Peter Riederer. J Neural Transm. 2022;129(5–6):627–642. doi:10.1007/s00702-022-02513-5
  45. Tanaka M, Szabó Á, Vécsei L. Integrating armchair, bench, and bedside research for behavioral neurology and neuropsychiatry: Editorial. Biomedicines. 2022;10(12):2999. doi:10.3390/biomedicines10122999
  46. Zhao K, Zhu BS, Gong W, et al. SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901. Arch Med Sci. 2013;6:990–998. doi:10.5114/aoms.2013.39790
  47. Saika S, Miyamoto T, Yamanaka O, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-κB, in treatment of corneal alkali burns in mice. Am J Pathol. 2005;166(5):1393–1403. doi:10.1016/S0002-9440(10)62357-7
  48. Sun YX, Dai DK, Liu R, et al. Therapeutic effect of SN50, an inhibitor of nuclear factor-κB, in treatment of TBI in mice. Neurol Sci. 2013;34(3):345–355. doi:10.1007/s10072-012-1007-z
  49. Chian CF, Chiang CH, Chuang CH, Liu SL, Tsai CL. SN50, a cell-permeable inhibitor of nuclear factor-κB, attenuates ventilator-induced lung injury in an isolated and perfused rat lung model. Shock. 2016;46(2):194–201. doi:10.1097/SHK.0000000000000563
  50. Shi B, Xue M, Wang Y, et al. An improved method for increasing the efficiency of gene transfection and transduction. Int J Physiol Pathophysiol Pharmacol. 2018;10(2):95–104. PMID:29755642.
  51. Xian Z, Yanhua H, Jingyi H, Yan W, Dingming S, Chenglong L. Optimization of transfection conditions of chicken primordial germ cells. Yi Chuan. 2021;43(3):280–288. doi:10.16288/j.yczz.20-212
  52. Kao YH, Chen YC, Cheng CC, Lee TI, Chen YJ, Chen SA. Tumor necrosis factor-α decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med. 2010;38(1):217–222. doi:10.1097/CCM.0b013e3181b4a854
  53. Qin Y, Hua M, Duan Y, et al. TNF-α expression in Schwann cells is induced by LPS and NF-κB-dependent pathways. Neurochem Res. 2012;37(4):722–731. doi:10.1007/s11064-011-0664-2
  54. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
  55. Bosseboeuf E, Raimondi C. Signalling, metabolic pathways and iron homeostasis in endothelial cells in health, atherosclerosis and Alzheimer’s disease. Cells. 2020;9(9):2055. doi:10.3390/cells9092055
  56. Ribatti D, Tamma R, Annese T. The role of vascular niche and endothelial cells in organogenesis and regeneration. Exp Cell Res. 2021;398(1):112398. doi:10.1016/j.yexcr.2020.112398
  57. Wang Y, Wang J, Yang J, et al. Study on protection of human umbilical vein endothelial cells from amiodarone-induced damage by intermedin through activation of Wnt/β-catenin signaling pathway. Oxid Med Cell Longev. 2021;2021:8889408. doi:10.1155/2021/8889408
  58. Xue M, Qiqige C, Zhang Q, et al. Effects of tumor necrosis factor α (TNF-α) and interleukin 10 (IL-10) on intercellular cell adhesion molecule-1 (ICAM-1) and cluster of differentiation 31 (CD31) in human coronary artery endothelial cells. Med Sci Monit. 2018;24:4433–4439. doi:10.12659/MSM.906838
  59. Kenny OM, McCarthy CM, Brunton NP, et al. Anti-inflammatory properties of potato glycoalkaloids in stimulated Jurkat and Raw 264.7 mouse macrophages. Life Sci. 2013;92(13):775–782. doi:10.1016/j.lfs.2013.02.006
  60. Liu Y, Tie L. Apolipoprotein M and sphingosine-1-phosphate complex alleviates TNF-α-induced endothelial cell injury and inflammation through PI3K/AKT signaling pathway. BMC Cardiovasc Disord. 2019;19(1):279. doi:10.1186/s12872-019-1263-4
  61. Gao H, Zhang Q, Chen J, et al. Porcine IL-6, IL-1β, and TNF-α regulate the expression of pro-inflammatory-related genes and tissue factor in human umbilical vein endothelial cells. Xenotransplantation. 2018;25(5):e12408. doi:10.1111/xen.12408
  62. Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-κB pathway for the therapy of diseases: Mechanism and clinical study. Sig Transduct Target Ther. 2020;5(1):209. doi:10.1038/s41392-020-00312-6
  63. Dorrington MG, Fraser IDC. NF-κB signaling in macrophages: Dynamics, crosstalk, and signal integration. Front Immunol. 2019;10:705. doi:10.3389/fimmu.2019.00705
  64. Deng HF, Wang S, Li L, et al. Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells. Biomed Pharmacother. 2018;104:261–267. doi:10.1016/j.biopha.2018.05.038
  65. Cheng J, Chen T, Li P, et al. Sodium tanshinone IIA sulfonate prevents lipopolysaccharide-induced inflammation via suppressing nuclear factor-κB signaling pathway in human umbilical vein endothelial cells. Can J Physiol Pharmacol. 2018;96(1):26–31. doi:10.1139/cjpp-2017-0023
  66. Hasanain M, Bhattacharjee A, Pandey P, et al. α-solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt/mTOR pathway. Cell Death Dis. 2015;6(8):e1860. doi:10.1038/cddis.2015.219
  67. Wen Z, Huang C, Xu Y, et al. α-solanine inhibits vascular endothelial growth factor expression by downregulating the ERK1/2-HIF-1α and STAT3 signaling pathways. Eur J Pharmacol. 2016;771:93–98. doi:10.1016/j.ejphar.2015.12.020
  68. Karaboğa Arslan A, Yerer M. α-chaconine and α-solanine inhibit RL95-2 endometrium cancer cell proliferation by reducing expression of Akt (Ser473) and ERα (Ser167). Nutrients. 2018;10(6):672. doi:10.3390/nu10060672
  69. Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The nuclear factor kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis. 2021;8(3):287–297. doi:10.1016/j.gendis.2020.06.005